同型がん細胞の薬物治療で様々なクローン運命をたどる
Yogesh Goyal1,2,3,4, Gianna T Busch5, Maalavika Pillai6,7,8
1Department of Cell and Developmental Biology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. yogesh.goyal@northwestern.edu.
Nature
|July 19, 2023
まとめ
癌細胞は 治療前に様々な抵抗性を持ち 固有の分子の違いによって 決まります 薬物治療は 治療結果に影響を及ぼし 前もって決定された抵抗性の運命を 変えることができます
科学分野:
- 癌 生物学
- ゲノミクス
- 薬剤耐性
背景:
- 治療への抵抗は稀な癌細胞のサブセットから生じます.
- 固有の分子の違いが 既存の抵抗を駆り立てます
- 耐性結果の変動性は十分に理解されていません.
研究 の 目的:
- 癌細胞の治療抵抗性の起源と多様性を調査する.
- 異なる抵抗性細胞の種類と,その事前の性質を特徴づけること.
- 薬による介入が 抵抗の運命にどう影響するかを調べる
主な方法:
- DNAバーコードと単細胞RNA配列を統合したFateMapを開発した.
- 何十万ものクローンの運命を 追跡した
- 耐性クローンの分子,形態,機能の特徴を分析した.
主要な成果:
- 耐性のあるクローンには 既定の分子型と機能型があります
- 外的な要因ではなく 内的な細胞状態が 主に抵抗の種類を決定します
- 薬の量とタイプは,特定の耐性型の生成と排除を調節する.
- 患者サンプルで様々な耐性菌が観察された.
結論:
- がん治療に対する耐性の多様性は,細胞の固有の状態の変動性から生じる.
- 前定の抵抗タイプは 外部信号に対する細胞の反応の一般的な特徴です
- これらの多様な抵抗メカニズムを理解することは 効果的ながん治療に不可欠です
関連する概念動画
Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer
48.8K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
48.8K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Cancers Originate from Somatic Mutations in a Single Cell
12.1K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.1K


